| 郑美玲,赵 冬,陈慧敏,朴仁女,倪 楠,宁 欣.非小细胞肺癌组织PRRX1、VASH-1与微血管密度、临床病理参数和预后的关系研究[J].现代生物医学进展英文版,2024,(2):348-352. |
| 非小细胞肺癌组织PRRX1、VASH-1与微血管密度、临床病理参数和预后的关系研究 |
| Study on the Relationship between PRRX1, VASH-1 and Microvessel Density, Clinicopathological Parameters and Prognosis in Non-Small Cell Lung Cancer Tissue |
| Received:July 23, 2023 Revised:August 18, 2023 |
| DOI：10.13241/j.cnki.pmb.2024.02.028 |
| 中文关键词: 非小细胞肺癌 PRRX1 VASH-1 微血管密度 临床病理特征 预后 |
| 英文关键词: non-small cell lung cancer PRRX1 VASH-1 Microvessel density Clinicopathological features Prognosis |
| 基金项目:辽宁省自然科学基金项目（2019-ZD-0427） |
|
| Hits: 320 |
| Download times: 256 |
| 中文摘要: |
| 摘要 目的：探讨非小细胞肺癌（NSCLC）组织配对相关同源框蛋白1（PRRX1）、血管抑制蛋白1（VASH-1）与微血管密度（MVD）、临床病理参数和预后的关系。方法：选择2018年1月至2020年1月辽宁省金秋医院行手术切除的156例NSCLC患者的癌组织及癌旁正常组织标本。应用免疫组织化学染色法检测癌组织及癌旁组织PRRX1、VASH-1的阳性表达率，并进行MVD计数。比较PRRX1阳性表达组/阴性表达组、VASH-1阳性表达组/阴性表达组MVD计数。分析PRRX1、VASH-1与NSCLC患者病理参数的关系。随访3年，应用Kaplan-Meier生存曲线分析PRRX1、VASH-1阳性/阴性表达与NSCLC患者预后的关系。结果：与癌旁组织相比，NSCLC患者癌组织PRRX1阳性表达率降低，VASH-1阳性表达率升高（P<0.05）。与PRRX1阴性NSCLC患者相比，PRRX1阳性NSCLC患者癌组织MVD降低，与VASH-1阴性NSCLC患者相比，VASH-1阳性NSCLC患者癌组织MVD升高（P<0.05）。与TNM I~II期、无淋巴结转移NSCLC患者的癌组织相比，TNM Ⅲ A期、淋巴结转移NSCLC患者的癌组织中PRRX1阳性表达率降低，VASH-1阳性表达率升高（P<0.05）。Kaplan-Meier法分析显示，PRRX1阳性组3年总体生存率（OS）、3年无病生存率（DFS）高于PRRX1阴性组（P<0.05），VASH-1阴性组3年OS、3年DFS高于VASH-1阳性组（P<0.05）。结论：NSCLC患者的癌组织中PRRX1阳性表达率降低，VASH-1阳性表达率升高，与淋巴结转移、TNM分期及不良预后有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between paired related homeobox 1 (PRRX1), vascular inhibitory protein (VASH-1) and microvessel density (MVD), clinicopathological parameters and prognosis in non-small cell lung (NSCLC) cancer tissue. Methods: Cancer tissues and paracancerous normal tissue specimens of 156 patients with NSCLC who underwent surgical resection in Liaoning Jinqiu Hospital from January 2018 to January 2020 were selected. Immunohistochemical staining method was applied, PRRX1 and VASH-1 positive expression rates in cancer tissues and adjacent tissues were detected, and MVD count was performed. The MVD counts in PRRX1 positive expression group/negative expression group and VASH-1 positive expression group/negative expression group were compared. The relationship between PRRX1, VASH-1 and pathological parameters of patients with NSCLC were analyzed. Relationship between PRRX1 and VASH-1 positive/negative expression and the prognosis of patients with NSCLC were analyzed by Kaplan-Meier survival curve after 3 years of follow-up. Results: Compared with adjacent tissues, PRRX1 positive expression rate was decreased in cancer tissues of patients with NSCLC, and VASH-1 positive expression rate was increased (P<0.05). Compared with PRRX1 negative patients with NSCLC, MVD in cancer tissues of PRRX1 positive patients with NSCLC decreased, compared with VASH-1 negative patients, MVD in cancer tissues of VASH-1 positive patients with NSCLC increased (P<0.05). Compared with TNM I~II stage and non-lymph node metastasis patients with NSCLC cancer tissues, PRRX1 positive expression rate in TNM IIIA and lymph node metastasis patients with NSCLC cancer tissues was decreased, and VASH-1 positive expression rate was increased (P<0.05). Kaplan-Meier analysis showed that, the 3-year overall survival (OS) and 3-year disease-free survival (DFS) in PRRX1 positive group were higher than those in PRRX1 negative group (P<0.05), and the 3-year OS and 3-year DFS in VASH-1 negative group were higher than those in VASH-1 positive group (P<0.05). Conclusion: The positive expression rate of PRRX1 in cancer tissues of patients with NSCLC is decrease, and the positive expression rate of VASH-1 is increase, which are relate to lymph node metastasis, TNM stage and poor prognosis. |
|
View Full Text
View/Add Comment Download reader |
| Close |
